WEBULL
WebtradeDownload

How Strong Earnings Will Impact argenx Stock Investors

Simply Wall St · 1d ago
  • argenx reported third quarter 2026 revenue of US$1.751b and net income of US$506m, with higher basic and diluted earnings per share from continuing operations compared with the same period in 2025.
  • The nine month figures show argenx generating US$4.605b of revenue and US$1.344b of net income, which gives investors more visibility into how the commercial model is scaling relative to its cost base over most of the financial year.
  • We will look at how argenx's investment narrative is affected by this strong year to date revenue and earnings performance.

Scan how argenx's earnings story compares with other potential breakout opportunities by reviewing the curated 601 high quality undiscovered gems that share strong fundamentals but remain off most investors' radar.

argenx Investment Narrative Recap

For argenx, the big picture to consider is a commercial story built around autoimmune disease treatments with VYVGART still at the center. The latest quarter and nine month figures show the model generating meaningful revenue and profit, which supports heavier R&D and commercial spend while maintaining earnings discipline.

The near term focus remains on execution for indication and geographic expansion for efgartigimod formats, along with visible progress across the broader autoimmune pipeline. The largest operational risk continues to be product concentration and competitive pressure in MG and CIDP. This earnings release does not remove that risk, even if it provides more comfort on current demand and margins.

The most relevant update alongside these results is argenx flagging participation in upcoming healthcare investor conferences in November 2026. Management time on that circuit keeps the financial story in front of institutions at the same moment the income statement is showing higher earnings and a scaled up top line.

For investors, those conferences function more as soft catalysts than hard ones. They give the leadership team a platform to clarify how they view competitive threats, pricing pressure, and pipeline milestones after this year to date period, which can influence expectations around both execution risk and the durability of argenx's current commercial trajectory.

What The Current Forecasts Assume For argenx

argenx's narrative projects US$10.3b revenue and US$3.1b earnings by 2029. That profile is based on analyst assumptions of 24.6% yearly revenue growth and an increase in earnings of about US$1.4b from US$1.7b today.

Uncover how argenx's fair value indicates a 24% potential upside to its current price before the market closes the gap.

ENXTBR:ARGX 1-Year Stock Price Chart
ENXTBR:ARGX 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view puts argenx’s cost base at the center of the story. The most cautious analysts were modeling profit margins closer to 11.5% by 2029 and earnings of about US$1.2b, even while using similar revenue assumptions. That is a much harsher read on future profitability. It shows how widely opinions can differ and why it helps to review several competing narratives that might now shift after these results.

Explore 5 other argenx fair value estimates, including one that suggests it could be worth just €775.78.

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.

Looking For More Investment Ideas Beyond argenx?

Once you have a handle on argenx, it can help to widen the lens and see how it stacks up against other potential opportunities. The Simply Wall St Screener lets you filter the market by quality, balance sheet strength, dividends, and more so you can build a watchlist that fits your approach.

  • If you are hunting for quality at a reasonable price, you can start with companies that combine strong fundamentals with potentially attractive valuations by reviewing the 194 high quality undervalued stocks.
  • If capital preservation sits high on your priority list, you can narrow your search to businesses with sturdier finances and a cleaner balance sheet profile using the list of solid balance sheet and fundamentals (198 results).
  • If income is a key part of your plan, you can focus on reliable cash generators with higher payout potential through the 215 dividend fortresses.